In PLOS this week: regulators of brown adipocyte differentiation, longevity and FOXO3 variants, and more.
The test is the fifth assay on the Solana platform to obtain clearance, and expands the firm's offerings in the women's health market.
The Public Health England lab plans to continue to use Oxford Nanopore's MinIon to help discover novel resistance mutations and elements that influence virulence.
Researchers use the CRISPR/Cas9 gene editing approach to limit herpesviruses replication.
The multiplex qPCR test can detect and discriminate herpes simplex virus 1 and 2 as well as varicella zoster virus, which can be mistaken for HSV in a proportion of cases.
The company issued the Class I recall in February because poor lamination between sample reaction wells led to inaccurate results, but has since resolved the issue.
The platform and the assay were cleared by the US Food and Drug Administration in October and were launched in the US shortly thereafter.
In PNAS this week: single-stranded cytosine deamination in E. coli, characterization of herpes simplex virus-1 microRNAs, and more.
The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.
The Australian firm provided an update on its in vitro diagnostics business, noting that it has also rebranded its core technologies and continues to license them.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.